04/10/2026
The FDA’s recent push to streamline biosimilar development may look like a manufacturer-side story at first glance, but it has real downstream 🔁 effects for infusion practices.
What FDA’s New Biosimilar Development Push Could Mean for Infusion Practices in 2026. Altus Biologics Partnering with Physicians to Provide Biologic Management Services